Table 6.
Univariate and multivariate analysis of prognostic factors for overall survival (OS) before and after PSM analysis.
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Before PSM | After PSM | Before PSM | After PSM | |||||
| Variables | Median OS (95% CI) | P value | Median OS (95% CI) | P value | Hazards ratio (95% CI) | P value | Hazards ratio (95% CI)r5 | P value |
| Gender | 0.729 | 0.396 | ||||||
| Male | 10.0 (9.0, 11.0) | 9.0 (8.0, 10.0) | ||||||
| Female | 7.0 (2.7, 11.3) | 8.0 (2.9, 13.1) | ||||||
| Age | 0.074 | 0.267 | ||||||
| ≤60 | 9.0 (6.8, 11.2) | 9.0 (7.8, 10.2) | ||||||
| >60 | 10.0 (8.5, 11.5) | 9.0 (7.6, 10.4) | ||||||
| ECOG performance | 0.922 | 0.738 | ||||||
| 1 | 9.0 (7.7, 10.3) | 9.0 (7.8, 10.2) | ||||||
| 2 | 10.0 (7.2, 12.8) | 10.0 (7.6, 12.4) | ||||||
| HBV infection | 0.402 | 0.972 | ||||||
| Yes | 10.0 (8.8, 11.2) | 9.0 (7.8, 10.2) | ||||||
| No | 10.0 (6.3, 13.7) | 10.0 (6.6, 13.4) | ||||||
| Child–Pugh class | 0.046 | 0.034 | ||||||
| A | 10.0 (8.7, 11.3) | 9.0 (7.9, 10.1) | ||||||
| B | 5.0 (2.3, 7.7) | 5.0 (3.0, 7.0) | ||||||
| Mild ascites | 0.001 | 0.111 | ||||||
| Absent | 10.0 (8.5, 11.5) | 9.0 (7.6, 10.4) | ||||||
| Present | 6.0 (3.1, 8.9) | 8.0 (5.4, 10.6) | ||||||
| AFP level (ng/ml) | 0.184 | 0.678 | ||||||
| >400 | 10.0 (8.4, 11.6) | 9.0 (7.7, 10.3) | ||||||
| ≤400 | 9.0 (7.3, 10.7) | 9.0 (7.5, 10.5) | ||||||
| Total bilirubin (μmol/L) | 0.383 | 0.276 | ||||||
| ≥34 | 9.0 (6.4, 11.6) | 8.0 (5.3, 10.7) | ||||||
| <34 | 10.0 (8.6, 11.4) | 9.0 (7.7, 10.3) | ||||||
| Albumin level (g/L) | 0.492 | 0.693 | ||||||
| >35 | 10.0 (8.1, 11.9) | 9.0 (7.4, 10.6) | ||||||
| ≤35 | 9.0 (7.3, 10.7) | 9.0 (7.1, 10.9) | ||||||
| PVTT | 0.022 | 0.263 | ||||||
| Absent | 11.0 (7.8, 14.2) | 9.0 (6.4, 11.6) | ||||||
| Present | 9.0 (7.6, 10.4) | 9.0 (7.6, 10.4) | ||||||
| HVTT | 0.584 | 0.578 | ||||||
| Absent | 10.0 (9.0, 11.0) | 9.0 (7.9, 10.1) | ||||||
| Present | 9.0 (7.2, 10.8) | 9.0 (6.9, 11.1) | ||||||
| Extrahepatic spread | 0.119 | 0.159 | ||||||
| Absent | 9.0 (7.6, 10.4) | 8.0 (6.8, 9.2) | ||||||
| Present | 10.0 (8.0, 12.0) | 10.0 (8.1, 11.9) | ||||||
| Treatment method | <0.001 | <0.001 | ||||||
| TACE–apatinib | 14.0 (12.1, 15.9) | 13.0 (10.3, 15.7) | ||||||
| TACE | 7.0 (6.2, 7.8) | 8.0 (7.3, 8.7) | ||||||
| Treatment method: | ||||||||
| TACE–apatinib | 0.34 (0.25, 0.45) | <0.001 | 0.35 (0.26, 0.49) | <0.001 | ||||
| Child–Pugh class: A | 0.68 (0.46, 1.0) | 0.059 | 0.65 (0.42, 0.99) | 0.058 | ||||
| Mild ascites: absent | 0.68 (0.48, 0.96) | 0.029 | NA | - | ||||
| PVTT: absent | 0.77 (0.57, 1.04) | 0.089 | NA | - | ||||
PSM, propensity score matching; ECOG, Eastern Cooperative Oncology Group; AFP, a-fetoprotein; TACE, transarterial chemoembolization; PVTT, portal vein tumor thrombus; HVTT, hepatic vein tumor thrombus.
-,no data; NA, not applicable.